Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.

Abstract

The classic pathogenesis of secondary hyperparathyroidism (SHPT) began with the trade-off hypothesis based on parathyroid hormone hypersecretion brought about by renal failure resulting from a physiological response to correct metabolic disorder of calcium, phosphorus, and vitamin D. In dialysis patients with failed renal function, physiological mineral balance control by parathyroid hormone through the kidney fails and hyperparathyroidism progresses. In this process, many significant genetic findings have been established. Abnormalities of Ca-sensing receptor and vitamin D receptor are associated with the pathogenesis of SHPT, and fibroblast growth factor 23 has also been shown to be involved in the pathogenesis. Vitamin D receptor activators (VDRAs) are widely used for treatment of SHPT. However, VDRAs have calcemic and phosphatemic effects that limit their use to a subset of patients, and calcimimetics have been developed as alternative drugs for SHPT. Hyperphosphatemia also affects progression of SHPT, and control of hyperphosphatemia is, therefore, thought to be fundamental for control of SHPT. Currently, a combination of a VDRA and a calcimimetic is recognized as the optimal strategy for SHPT, and for other outcomes such as reduced cardiovascular disease and improved survival. The latest findings on the pathogenesis and treatment of SHPT are summarized in this review.

• Authors: Masahide Mizobuchi, Hiroaki Ogata, Fumihiko Koiwa
• Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 23 Issue 4 Pg. 309-318 (Aug 2019) ISSN: 1744-9987 [Electronic] Australia
• PMID: 30411503 (Publication Type: Journal Article, Review)
• Copyright: © 2018 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Chemical References

• Bone Density Conservation Agents
• Calcimimetic Agents
• Parathyroid Hormone
• Vitamin D
• Phosphorus
• Calcium

Topics

• Bone Density Conservation Agents (pharmacology)
• Calcimimetic Agents (pharmacology)
• Calcium (metabolism)
• Humans
• Hyperparathyroidism, Secondary (diagnosis, etiology, metabolism, therapy)
• Parathyroid Hormone (metabolism)
• Phosphorus (metabolism)
• Renal Dialysis (adverse effects, methods)
• Renal Insufficiency (complications, therapy)
• Vitamin D (metabolism)